Mikra Applies to Health Canada for CELLF 2.0 NPN
Mikra Applies to Health Canada for CELLF 2.0 NPN
TORONTO, July 08, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. ("Lifeist" or the "Company") (TSXV: LFST) (FRANKFURT: M5B0) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, reports that its U.S. biosciences subsidiary Mikra Cellular Sciences Inc. ("Mikra") has filed a Natural Health Product License Application ("PLA") with Health Canada, seeking a Natural Product Number ("NPN") for its best-selling cellular health product CELLF 2.0.
Lifeist Wellness公司(“Lifeist”或“公司”)(TSXV:LFST)(FRANKFURT:M5B0)(OTCMKTS:LFSWF)是一家健康科技公司,利用科学和技术的进步来构建突破性的企业,以改变人类的健康状况。公司的美国生物科学子公司Mikra Cellular Sciences Inc.(“Mikra”)已向加拿大卫生部提出自然健康产品许可申请(“PLA”),寻求其畅销的细胞健康产品CELLF 2.0的天然产品编号(“NPN”)批准。
"We're pleased to announce that Mikra has applied to Health Canada for an NPN for CELLF 2.0," said Andrea Judge, CEO of Mikra. "Receiving this NPN will allow us to market and promote CELLF 2.0 throughout Canada, both directly and via multiple other sales channels. We look forward to successfully navigating the Health Canada application process and wish to thank our experienced advisors at KGK Science Inc. for their sound guidance throughout the preparation and drafting of our application."
Mikra的首席执行官安德烈娅·詹奈特(Andrea Judge)表示:“我们很高兴宣布Mikra已向加拿大卫生部申请CELLF 2.0的NPN。获得此NPN将使我们能够通过多个其他销售渠道在加拿大市场和推广CELLF 2.0。我们期待成功地通过卫生部的申请过程,并感谢我们在申请准备和起草期间的有经验的KGk Science Inc.顾问为我们提供的有益指导。”
CELLF 2.0 provides a complete adult daily dose of Pyrroloquinoline Quinone (PQQ) and Glutathione, alongside the recommended dose of bioavailable CoQ10, in a liposomal gel that is precision engineered to protect all of these key molecules from the corrosive effects of stomach acid, delivering them safely to be absorbed by the small intestine and guaranteeing that the full clinical dose becomes bioavailable. The latest published research confirms the vital role played by CELLF 2.0's key ingredients.
CELLF 2.0提供了一种完整的吡咯烷醌(PQQ)和谷胱甘肽的成人每日剂量,以及可生物利用的辅酶Q10的推荐剂量,在一个精密的脂质体凝胶中,该凝胶被精密地设计以保护所有这些关键分子免受胃酸的腐蚀作用,从而使它们安全地被小肠吸收,并确保全面的临床剂量成为生物利用。最近发布的研究证实了CELLF 2.0的关键成分所起的重要作用。
In 2023 a double-blind, randomized controlled trial completed in Japan found1:
2023年,日本进行了一项双盲、随机对照试验,结果如下1:
After 12 weeks, the participants showed improvements in composite memory and verbal memory... In younger adults (aged 20-40 years), PQQ improved cognitive function (cognitive flexibility, processing speed, and execution speed) after 8 weeks... Older adults (aged 41-65 years) showed improvements in complex and verbal memory after 12 weeks.
经过12周的治疗,参与者在组合记忆和词语记忆方面取得了进步……在年轻人(20-40岁)中,PQQ在8周后改善了认知功能(认知灵活性,处理速度和执行速度)……年长者(41-65岁)在12周后显示了复杂和语言记忆的改善。
In 2023 a study conducted jointly at Canadian and Chinese research universities concluded2:
2023年,在加拿大和中国研究大学的共同研究中2证明:
This study reveals the underlying mechanism of PQQ's strong antioxidant capacity and provides evidence for PQQ as a potential agent for clinical prevention and treatment of natural aging-induced osteoporosis.
这项研究揭示了PQQ具有强抗氧化能力的潜在机制,并为PQQ作为治疗自然老化诱导的骨质疏松症的潜在药物提供了证据。
In 2023 a comprehensive research review completed at a medical university in Italy determined3:
2023年,在意大利的一所医学大学完成了一项全面的研究3:
There is evidence of enhanced glutathione levels in elderly subjects with excellent physical and mental health status, suggesting that heightened glutathione may be a marker and even a causative factor of increased healthspan and lifespan. Such aspects, and much more including glutathione-boosting substances administrable to humans, are considered in this state-of-the-art review, which deals with glutathione and glutathione-dependent enzymes from biochemistry to gerontology, focusing attention also on lifespan/healthspan extension and successful aging; the significance of glutathione levels in aging is considered also in relation to therapeutic possibilities and supplementation strategies... Aimed at increasing glutathione and related defenses to improve health status and counteract aging processes in humans.
对于老年人身体和精神健康状况良好的受试者,存在提高谷胱甘肽水平的证据,表明增高的谷胱甘肽可能是健康寿命和寿命增加的标志甚至是其成因因素。这篇最先进的综述评价了从生物化学到老年学的谷胱甘肽和谷胱甘肽依赖酶,关注寿命/健康寿命延长和成功衰老方面的一些问题,同时考虑谷胱甘肽水平在老化中的意义,关注治疗可能性和补充策略……旨在增加谷胱甘肽和相关防御来提高人类健康状况并抵御衰老过程。
CELLF 2.0 is a clinically validated formula proven to boost energy and focus on a cellular level, while protecting against the negative effects of oxidative stress. Meticulously researched, the precision-engineered formula is designed to add healthy, energetic years to your life, so you can feel better, longer. Lifeist is committed to bringing natural products backed by real science to market and looks forward to reaching many more customers in 2024.
CELLF 2.0是一种经过临床验证的处方,被证明可以在细胞水平上提高能量和专注力,并保护免受氧化应激的负面影响。这种精密制造的处方经过仔细的研究,旨在为您的生活增加健康、充满活力的岁月,让您感觉更好、更长久。Lifeist致力于推出受真正科学支持的天然产品,并期待在2024年获得更多的客户。
About Lifeist Wellness Inc.
关于Lifeist Wellness Inc。
Sitting at the forefront of the post-pandemic wellness revolution, Lifeist leverages advancements in science and technology to build breakthrough companies that transform human wellness. Portfolio business units include Mikra, a biosciences and consumer wellness company developing and selling innovative products for cellular health, and CannMart, which operates a B2B wholesale distribution business facilitating recreational cannabis sales to Canadian provincial government control boards including for CannMart Labs, a BHO extraction facility producing high margin cannabis 2.0 products.
作为后疫情时代健康领域革命的先锋,Lifeist利用科学和技术的进步来建立突破性的企业,改变人类健康状况。投资组合业务单元包括Mikra,一家生物科学和消费者健康公司,开发和销售面向细胞健康的创新产品,以及CannMart,这是一家B2B亿的批发销售分销业务,为加拿大省政府控制委员会提供娱乐大麻销售,包括CannMart Labs,这是一家生产高利润的大麻2.0产品的BHO提取设施。
Information on Lifeist and its businesses can be accessed through the links below:
Lifeist及其业务的信息可以通过以下链接访问:
Contact:
Meni Morim
CEO
Brian Siegel,IRC,MBA-高级管理董事,Hayden IR,电话:(346)396-8696,ir@zedge.net
Meni Morim
首席执行官
Lifeist Wellness Inc.
Lifeist Wellness Inc。
Ph: 647-362-0390
Email: ir@lifeist.com
电话:647-362-0390
邮箱:ir@lifeist.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.
TSX Venture Exchange及其监管服务提供商(根据TSX Venture Exchange的政策定义)不接受对本发布内容的充分性或准确性的责任,也没有以任何方式批准或否认本新闻发布的内容。
Forward Looking Information
前瞻性信息
This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as "may", "expect", "likely", "should", "would", "plan", "anticipate", "intend", "potential", "proposed", "estimate", "believe" or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions "may" or "will" happen.
本新闻发布含有适用证券法律法规下的“前瞻性信息”。本文所包含的非历史性语句均提供前瞻性信息。前瞻性信息可以通过诸如“可能”、“预计”、“有望”、“应当”、“将会”、“计划”、“预料”、“旨在”、“潜力”、“建议”、“估计”、“相信”等用语或短语来确定,亦可通过其他类似的单词、表达方式或语法变体,或声明某些事件或条件“可能”发生或“将会”发生的语句来确定。
The forward-looking information contained herein, including, without limitation, statements related to Mikra reaching additional customers in 2024, are made as of the date of this news release and are based on assumptions management believed to be reasonable at the time such statements were made, including without limitation, the effectiveness and benefits of CELLF 2.0 are as anticipated, customer interest in Mikra's products including CELLF 2.0 and resulting sales will be as anticipated, its expectation that the nutraceutical market will develop as currently anticipated, the nutraceutical market will continue to be a multi-billion dollar high-margin market, the introduction of new products and brands will generate additional revenue, expectations that CELLF, CELLF 2.0, RESCUE, SERENITY, PROTECT and other new nutraceutical products to be developed by Mikra will gain market acceptance along with the expansion of the market for nutraceutical products, as well as other considerations that are believed to be appropriate in the circumstances. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. Such factors include, without limitation: customer uptake and resulting sales of CELLF 2.0 failing to materialize as anticipated, the inability of the Company to develop Mikra's business as anticipated, unanticipated changes to current regulations that would adversely impact Mikra's business, unforeseen developments that would delay Mikra's ability to sell newly developed nutraceutical products, the risk that the expected demand for nutraceutical products in general and those of Mikra in particular does not develop as anticipated and risks relating to the Company's ability to execute its business strategy and the benefits realizable therefrom. Additional risk factors can also be found in the Company's current MD&A filed under the Company's SEDAR+ profile at . Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
此处的前瞻性信息,包括但不限于Mikra在2024年获得更多客户的声明,是在本新闻发布日期作出的,基于管理层在发表此类声明时认为的合理假设,包括但不限于CELLF 2.0的效力和效益如预期,客户对Mikra的产品,包括CELLF 2.0,感兴趣,导致销售如预期,它预计保健品市场将按目前的预期发展,保健品市场将继续是一个价值数十亿美元的高利润市场,引入新产品和品牌将产生额外的收入,预计Mikra将开发的CELLF、CELLF 2.0、RESCUE、SERENITY、PROTECt等新的保健品将得到市场认可,同时保健品市场也将扩大等等。虽然我们认为这些假设是合理的,基于管理层目前可获得的信息,但没有保证这些期望将被证明是正确的。由于前瞻性信息的某些本质特征会产生一般或特定的固有风险和不确定性,在某些情况下,会导致预期、预测、预测、投射或结论不正确,假设可能是不正确的,目标、战略目标和优先事项可能无法实现。各种因素,包括已知和未知的风险,其中许多是我们无法控制的,都可能导致前瞻性信息在本新闻发布中的准确性与真实性不同。此类因素包括但不限于以下内容:CELLF 2.0的客户增长和随之而来的销售未能如预期般出现,公司无法按预期发展Mikra的业务,当前法规发生意外变化,将对Mikra的业务造成不利影响,预计需要更长时间才能销售新开发的保健品,预测保健品市场总体需求和Mikra在特定需求方面的产品不会如预期增长,以及与公司业务战略的执行以及实现其所带来的收益相关的风险。可以在Sedar +档案下的公司当前MD&A中找到其他风险因素。请读者注意,不要过分依赖前瞻性信息。该公司不承担更新或修订任何前瞻性信息的义务,除非适用法律有要求。本新闻发布中的前瞻性陈述显然受到此警告声明的限制。
Source: Lifeist Wellness Inc.
资讯来源: Lifeist Wellness Inc.
1 Pyrroloquinoline quinone improves brain function in both younger and older adults
1 Pyrroloquinoline quinone improves brain function in both younger and older adults
2 Pyrroloquinoline quinone alleviates natural aging-related osteoporosis
2 Pyrroloquinoline quinone alleviates natural aging-related osteoporosis
3 Glutathione and glutathione-dependent enzymes: From biochemistry to gerontology and successful aging
3 Glutathione and glutathione-dependent enzymes: From biochemistry to gerontology and successful aging